This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Bloomberg Law’s combination of innovative analytics, research tools and practical guidance provides you with everything you need to be a successful litigator.
AbbVie Inc. must pay $38 million to the family of a teenager whose birth defects were caused by in utero exposure to Depakote, the Missouri Supreme Court ruled ( Barron v. Abbott Labs., Inc. , 2017 BL 320656, Mo. en banc, No. SC96151, 9/12/17 ).
Calling the 2015 jury trial fair, the entire high court Sept. 12 upheld the award of $15 million in compensatory damages and $23 million in punitive damages to the family of Maddison Schmidt. Her family said the antiepilepsy drug caused her spina bifida.
The suit was filed against Depakote maker Abbott Laboratories Inc., which had no comment on the state Supreme Court decision other than to note that AbbVie was responsible for litigation over the drug.
Abbott spun off its branded-drug business into AbbVie in 2013, which is a separate public company. AbbVie didn’t respond to a request for comment.
The state high court found the compensatory damages award was based on proof the Depakote label failed to warn that the product posed a “considerably higher risk of overall birth defects than other antiepileptic drugs.”
Punitive damages were supported by evidence that Abbott “deliberately disregarded” the safety of Depakote users because it was “motivated by profits,” the court said.
Defense arguments that the trial judge should have transferred the trial from St. Louis to a neighboring county also were rejected.
Abbott’s headquarters are in Illinois and the child’s mother ingested Depakote in Minnesota, yet the Schmidt family was able to consolidate their claim with those of Depakote plaintiffs with more obvious connections to Missouri.
Abbott even argued that St. Louis, where many high-profile plaintiff’s awards have been rendered, was “biased in general” toward the defendant, the court said. But it failed to identify any particular ruling by the trial court suggesting bias or any particular juror who should have been disqualified for bias, the court said.
Abbott can’t show it was harmed “simply because a fair judge and jury in the city of St. Louis rendered the judgment and verdict rather than a fair judge and jury in St. Louis County,” the court said.
As Abbott waived personal jurisdiction, the U.S. Supreme Court’s recent decision on jurisdiction in Bristol-Myers Squibb Co. v. Superior Court of California had no application to this appeal, the state court said in a footnote.
Judge Paul C. Wilson wrote separately that the plaintiff’s use of Missouri Rule 52.05(a), to combine multiple in-state and out-of-state plaintiffs in a single action, “largely will be prevented in the future by Bristol-Myers Squibb.”
Plaintiffs’ attorneys include Bartimus, Frickleton, and Robertson, and Williams Kherkher Hart Boundas.
Abbott’s attorneys include Armstrong Teasdale, Bryan Cave, and Venable.
To contact the reporter on this story: Bruce Kaufman in Washington at bkaufman@bna.com
To contact the editor responsible for this story: Steven Patrick at spatrick@bna.com
Full text at http://src.bna.com/svB
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to books@bna.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to research@bna.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)